Prevents pregnancy. ANDA 209297, held by Glenmark Speclt. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 209297 (Hailey 1.5/30), held by Glenmark Speclt, was first approved by FDA on Jun 5, 2018, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Hailey 1.5/30 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 5, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hailey 1.5/300.03MG;1.5MG · tablet;oral-21 | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Aug 23, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 23, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 5, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters